[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retroperitoneal-sarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retroperitoneal-sarcoma":311},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,66,107,131,165,195,222,244,263,283],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100518069",false,"NCT06025747","A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas","A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for High-Risk Adipocytic Retroperitoneal Sarcomas","Inclusion Criteria:\n\n* Subjects, \\>= 18 years old, must have newly diagnosed or locally recurrent MDM2 or CDK4-amplified adipocytic sarcoma as determined by fluorescence in situ hybridization (FISH), or other clinically appropriate methodology in the opinion of the reviewing pathologist. Histologic or imaging evidence of the presence of a dedifferentiated component must be present\n* Subjects must have one or more measurable target lesions by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), assessed via CT scan or MRI\n* At the time of study enrollment, subjects must have a tumor burden that is judged to be surgically resectable\n* Have plans to undergo neoadjuvant radiation therapy followed by surgical resection. Review and approval of final treatment plans for subjects receiving radiotherapy locally\u002Fat an outside institution must be reviewed and approved by a radiation oncologist investigator prior to initiation of radiotherapy\n* Absolute neutrophil count (ANC) \\>= 1500\u002Fmm\\^3 (\\>= 1.5 GI\u002FL) without granulocyte colony-stimulating factor support in the last 14 days (subjects may not have received blood product transfusion or granulocyte colony-stimulating factor \\[G-CSF\\] within 14 days prior to screening)\n* White blood cell count \\>= 2500\u002Fmm\\^3 (\\>= 2.5 GI\u002FL) (subjects may not have received blood product transfusion or G-CSF within 14 days prior to screening)\n* Platelets \\>= 100,000\u002Fmm\\^3 (\\>= 100 GI\u002FL) (subjects may not have received blood product transfusion or G-CSF within 14 days prior to screening)\n* Hemoglobin \\>= 8 g\u002FdL (\\>= 80 g\u002FL) (subjects may not have received blood product transfusion or G-CSF within 14 days prior to screening)\n* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =\\\u003C 3 x upper limit of normal (ULN) (subjects may not have received blood product transfusion or G-CSF within 14 days prior to screening)\n* Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN) (subjects with Gilbert's disease =\\\u003C 2 x ULN and direct bilirubin within normal limits are permitted) (subjects may not have received blood product transfusion or G-CSF within 14 days prior to screening)\n* Serum albumin \\>= 2.8 g\u002Fdl (subjects may not have received blood product transfusion or G-CSF within 14 days prior to screening)\n* Serum creatinine =\\\u003C 2.0 x ULN or calculated creatinine clearance \\>= 30 mL\u002Fmin (\\>= 0.5 mL\u002Fsec) using the Cockcroft-Gault equation (subjects may not have received blood product transfusion or G-CSF within 14 days prior to screening)\n* Urine protein\u002Fcreatinine ratio (UPCR) =\\\u003C 1 mg\u002Fmg (=\\\u003C 113.2 mg\u002Fmmol) (subjects may not have received blood product transfusion or G-CSF within 14 days prior to screening)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Male or non-pregnant and non-breast feeding female:\n\n  * Women of child-bearing potential (WOCBP) must agree to use highly effective contraception without interruption from initiation of therapy and continue until 4 months (120 days) after last dose of study therapy. WOCBP must have a negative serum pregnancy test (beta-human chorionic gonadotropin \\[hCG\\]) result at screening and agree to ongoing pregnancy testing during the study, and at the end of study treatment. A highly effective method of contraception is defined as one that results in a low failure rate (that is, \\\u003C 1% per year), when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner\n  * Male subjects must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study\n* Life expectancy of \\> 3 months, as determined by the investigator\n* Ability to understand and sign informed consent\n* Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures\n\nExclusion Criteria:\n\n* Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) for the investigational diagnosis\n* Receipt of any prior radiation therapy for any reason to the affected area\n* Known central nervous system (CNS) metastases\n* Evidence of distant metastatic disease at time of treatment initiation\n* History of thromboembolic event within 1 year of treatment initiation. Thromboembolic events include, but are not limited to, deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, and inferior vena cava thrombosis\n* History of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest\n* History of any major surgery within 14 days prior to enrollment\n* Receipt of ongoing anti-coagulation for treatment or prophylaxis of thromboembolic event in the setting of prior thromboembolic event\n* History of interstitial lung disease\n* Subjects with serious and\u002For uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \\[e.g. estimated creatinine clearance \\\u003C 30ml\u002Fmin\\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea)\n* Pregnant or lactating females\n* Inability to swallow tablets\n* Previously identified allergy or hypersensitivity to components of the study treatment formulations\n* Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized tumors deemed cured and not treated with systemic therapy\n* Concurrent use of medications (especially those interacting with CYP3A) that potentially interact unsafely with abemaciclib which cannot be discontinued or substituted\n* Recent infection requiring systemic anti-infective treatment that was completed =\\\u003C 14 days prior to enrollment (except for uncomplicated urinary tract infection or upper respiratory tract infection). Any active systemic bacterial infection (requiring intravenous \\[IV\\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \\[for example, hepatitis B surface antigen positive\\]. Screening for human immunodeficiency virus (HIV)\u002Fhepatitis is not required for enrollment\n* Concurrent enrollment in any other type of medical research (for example: medical device) judged by the investigator not to be scientifically or medically compatible with this study","ALL","18 Years",{"count":18,"type":19},18,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","This phase I trial tests the safety, side effects, and best dose of abemaciclib and how well it works with radiation therapy before surgery in treating patients with high-risk adipocytic retroperitoneal sarcoma. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving abemaciclib together with radiation therapy before surgery may shrink tumors in patients with high-risk adipocytic retroperitoneal sarcoma.",[25,26,27],"Retroperitoneal Sarcoma","Liposarcoma","Dedifferentiated Liposarcoma","RECRUITING","2026-06-08",{"date":31,"type":32},"2026-06-11","ACTUAL",{"date":34,"type":32},"2025-03-19",{"date":36,"type":19},"2029-03-03",{"name":38,"class":39},"University of Washington","OTHER",1,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100364933","NCT04031677","Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)","STRASS2","1. STRASS 2\n\n   Inclusion Criteria:\n   * Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of retroperitoneal space or infra-peritoneal spaces of pelvis.\n   * LMS:\n\n     * Any grade LMS can be included\n     * Minimum size of LMS tumor should be 5 cm\n   * LPS:\n\n     * Diagnosis should be confirmed based on MDM2 (Mouse double minute 2 homolog) and CDK4 (Cyclin-dependent kinase 4) expression on IHC (immunohistochemistry), while proof of MDM2 amplification is highly recommended.\n     * All grade 3 DDLPS can be included.\n     * DDLPS with confirmed grade 2 on biopsy can be included when:\n\n       * The grade 2 DDLPS has an FNCLCC score=5 (Fédération Nationale des Centres de Lutte Contre Le Cancer), and clear necrosis on imaging (whether or not present on the biopsy).\n       * The tumors carry a high risk gene profile as determined by the Complexity INdex in SARComas (CINSARC-high)\n     * Unifocal tumour\n     * Resectable tumour: resectability is based on pre-operative imaging (CT-abdomen, potentially also with MRI) and has to be defined by the local treating sarcoma team. A patient is not considered resectable when the expectation is that only an R2 resection is feasible.\n     * Criteria for non-resectability are:\n     * Involvement of the superior mesenteric artery, aorta, coeliac trunk and\u002For portal vein\n     * Involvement of bone\n     * Growth into the spinal canal\n     * Progression of retro-hepatic inferior vena cava leiomyosarcoma towards the right atrium\n     * Infiltration of multiple major organs like liver, pancreas and or major vessels\n     * Patient must have radiologically measurable disease (RECIST 1.1), as confirmed by imaging. CT thorax abdomen pelvis with IV contrast is the preferred imaging modality. In case of any contra-indications (medical or regulatory), it is allowed to perform a non-contrast CT thorax + MRI abdomen \\& pelvis\n     * Collection of tumour tissue for central pathology review is mandatory.\n     * For patients with LMS: if there is not enough tissue for assessing the grading, this is acceptable.\n     * If tumour tissue is not available for the central pathology review, patient will not be eligible.\n     * If the biopsy was not done or the FFPE of the biopsy not available but at least 10 unstained slides or one pathological block are available for the central review, that will be considered as acceptable.\n     * For the biopsy if fine needle aspiration (FNA) is performed instead of core needle biopsy (CNB) recommended by the standard guidelines, please contact the EORTC medical monitors for further evaluation.\n     * Collection of tumour tissue and blood samples for translational research is mandatory.\n     * In case there is not enough tissue for TR, a new biopsy is not required and if the patient fulfils all other eligibility criteria, he\u002Fshe will be eligible.\n     * If the blood samples are not collected, patient will not be eligible.\n     * If the patient refuses the collection of biomaterial for TR, patient will not be eligible even if he\u002Fshe fulfils all other eligibility criteria\n     * ≥ 18 years old (no upper age limit)\n     * WHO performance status ≤ 2\n     * Adequate haematological and organ function\n     * American Society of Anaesthesiologist (ASA) score \\\u003C 3\n     * Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 3 days prior to randomization.\n\n   Note: a woman is considered of childbearing potential, i.e., fertile, if she is following menarche. She remains of childbearing potential until she becomes post-menopausal or permanently sterile.Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.\n\n   A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 consecutive months without menses, a single FSH measurement is insufficient.\n   * WOCBP in both arms should use highly effective birth control measures, during the study treatment period and for at least 6 months after the last dose of chemotherapy or date of surgery (except for women receiving chemotherapy with ifosfamide who should continue contraception until 1 year after last day of treatment). A highly effective method of birth control is defined as a method which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly.\n   * For men in the experimental arm: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.\n   * Female subjects who are breast feeding should discontinue nursing prior to the first day of study treatment and until 6months after the last study treatment.\n   * Before patient randomization, written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n\n   Exclusion criteria:\n   * Sarcoma originating from bone structure, abdominal or gynecological viscera\n   * Extension through the sciatic notch or across the diaphragm\n   * Metastatic disease\n   * Any previous surgery (excluding diagnostic biopsy), radiotherapy or systemic therapy for the present tumour\n   * Hypersensitivity to doxorubicin, ifosfamide, dacarbazine or to any of their metabolites or to any of their excipients\n   * Congestive heart failure\n   * Angina pectoris\n   * Myocardial infarction within 1 year before randomization\n   * Uncontrolled arterial hypertension defined as blood pressure ≥ 150\u002F100 mm Hg despite optimal medical therapy.\n\n   Note: in case of high blood pressure: 1) initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; 2) blood pressure must be re-assessed on two occasions that are separated by a minimum of 1 hour. The mean SBP \u002F DBP values from each blood pressure assessment must be ≤ 150\u002F90mmHg in order for a patient to be eligible for the study.\n   * Uncontrolled cardiac arrhythmia\n   * Previous treatment with maximum cumulative doses (450mg\u002Fm² Doxorubicin or equivalent 900mg\u002Fm² Epirubicin) of doxorubicin, daunorubicin, epirubicin, idarubicin, and\u002For other anthracyclines and anthracenediones\n   * Active and uncontrolled infections\n   * Vaccination with live vaccines within 30 days prior to study entry\n   * Inflammation of the urinary bladder (interstitial cystitis) and\u002For obstructions of the urine flow.\n   * Other invasive malignancy within 5 years, with the exception of adequately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason ≤ 6prostate cancer.\n   * Uncontrolled severe illness, infection, medical condition (including uncontrolled diabetes), other than the primary LPS or LMS of the retroperitoneum.\n   * Female patients who are pregnant or breastfeeding or female and male patients of reproductive potential who are not willing to employ effective birth control method.\n   * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial\n   * Known contraindication to imaging tracer and to MRI\n2. Selection criteria for STREXIT 2\n\n   * Patients with histologically proven primary resectable localized high-risk DDLPS or LMS of retroperitoneal space or infra-peritoneal spaces of pelvis (as described in the inclusion criteria of STRASS 2) and amenable to receive chemotherapy but for whom the list of eligibility criteria for the study is too restrictive (tumour grading not available, inadequate organ function, concomitant diseases)\n   * Patients who meet all eligibility criteria of STRASS 2 but do not consent to randomization or are not enrolled for any other reason.\n   * Patients enrolled in a Registry collecting data on primary RPS patients in the centres participating in STRASS 2 (e.g., RESAR) and who satisfy the above criteria.\n3. Selection criteria for preferences for neoadjuvant chemotherapy in STRASS 2 substudy\n\nAll patients recruited to STRASS 2 in participating centres (Australia +\u002F- international sites) that are able to read, comprehend and write in English at a sufficient level to complete study materials.",{"count":49,"type":19},250,[51],"PHASE3","This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.\n\nAfter confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.",[25,26,54],"Leiomyosarcoma","2026-05-20",{"date":57,"type":32},"2026-05-22",{"date":59,"type":32},"2021-01-20",{"date":61,"type":19},"2028-04-21",{"name":63,"class":64},"European Organisation for Research and Treatment of Cancer - EORTC","NETWORK",169,{"id":67,"slug":4,"hasResults":10,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":20,"phases":75,"briefSummary":77,"conditions":78,"keywords":90,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":40},"100573965","NCT06753136","Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and\u002For Secondary Visceral Localizations, of Any Histotype","Treatment of Visceral Localizations With Electrochemotherapy in Patients With Primary Visceral Tumors and\u002For Secondary Visceral Localizations, of Any Histotype: Monocenter, Single Arm, Clinical Investigation","Inclusion Criteria:\n\n* Male\u002FFemale ≥ 18 years\n* Ability to understand the proposed treatment and express an informed acceptance by signing the informed consent\n* Diagnosis of primary and\u002For secondary visceral localizations of any histotype\n* Patients who are not eligible for standard curative procedures\n\nExclusion Criteria:\n\n* Absolute contraindications to invasive procedures\n* Concomitant presence of brain, lung, bone metastases\n* Uncorrectable coagulation changes\n* Bleomycin allergy\n* Absolute contraindications to taking Bleomycin\n* Poor respiratory function or pulmonary fibrosis\n* Acute lung infections\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study","99 Years",{"count":74,"type":19},24,[76],"NA","This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneous metastases of different tumor histotypes.\n\nAlthough still limited, the various experiences in the treatment of visceral localizations, particularly in liver metastases from colorectal cancer are promising and show that electrochemotherapy is a safe treatment, even in the case of lesions near large vessels or nerves. The investigators therefore propose a clinical investigation with a Medical Device according to EU Regulation 745\u002F2017, using electrochemotherapy (Cliniporator) with bleomycin for the treatment of visceral, primary or secondary, unresectable localizations, with percutaneous or intraoperative technique (laparoscopic or laparotomy), as needed.",[79,80,81,82,83,84,25,85,86,87,88,89],"Primary Visceral Tumors of Any Histotype","Visceral Lesions","Liver Cancer","Liver Metastasis Colon Cancer","Melanoma","Primary Pancreatic Tumor","Abdominal and\u002For Peritoneal Localizations","Merkel Cell Carcinoma","Squamous Cell Carcinoma","Secondary Visceral Localizations of Any Histotype","Non-melanoma Skin Cancer",[91,92,93,94,95,96,97],"electrochemotherapy","visceral lesions","Laparoscopic procedure","Laparotomic procedure","Percutaneous procedure","bleomycin","medical device","2026-04-09",{"date":100,"type":32},"2026-04-13",{"date":102,"type":32},"2025-07-23",{"date":104,"type":19},"2030-02-28",{"name":106,"class":39},"Istituto Oncologico Veneto IRCCS",{"id":108,"slug":4,"hasResults":10,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":20,"phases":115,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100183136","NCT01659203","Proton or Photon RT for Retroperitoneal Sarcomas","Phase I\u002FII Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) With Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas","Inclusion Criteria:\n\n* Histologically proven primary soft tissue sarcoma of the retroperitoneum\n* Measurable disease\n* Life expectancy of greater than 2 years\n\nExclusion Criteria:\n\n* Prior radiation therapy for retroperitoneal sarcoma\n* Pregnant or breastfeeding\n* Chemotherapy within 4 weeks prior to entering study\n* Receiving other investigational agents\n* Other types of sarcomas\n* Multifocal disease, lymph node or distant metastases\n* History of sensitivity to radiation therapy\n* Uncontrolled intercurrent illness\n* History of a different invasive malignancy within the past 3 years\n* HIV positive on combination anti-retroviral therapy",{"count":114,"type":19},80,[22,116],"PHASE2","This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational intervention. Phase I studies also try to define the appropriate dose of the investigational therapy to use for further studies. \"Investigational\" means that the intervention is still being studied and that research doctors are trying to find out more about it.\n\nRetroperitoneal sarcomas are soft tissue tumors located at the far back of the abdomen. Typically, patients with retroperitoneal sarcomas either have surgery for the removal of their tumors alone, or have their tumors removed, followed by standard radiation therapy, or have pre-operative radiation followed by surgery. When conventional radiation therapy is delivered after surgery, it can damage normal tissue. In this study, you will undergo proton beam radiation therapy or IMRT before undergoing surgery for the removal of your tumor.\n\nProton radiation and IMRT are FDA approved radiation delivery systems. Protons are tiny particles with positive charge that can be controlled to travel a certain distance and stop inside the body. In theory, this allows better control of where the radiation dose is delivered as compared to photons. Since proton radiation is more targeted, it may help to reduce unwanted side effects from radiation.\n\nIn this study, a standard dose of radiation will be given to the majority of the tumor, while a simultaneously integrated boost of additional radiation will be given to certain areas of the tumor identified as higher risk. This means that a higher radiation dose will be given to the higher risk areas of the tumor.\n\nThe purpose of this study is to determine the highest dose of radiation therapy with protons or IMRT that can be delivered safely in patients with retroperitoneal sarcomas and the effectiveness of proton beam radiation therapy as an intervention for patients with retroperitoneal sarcomas.",[25],[120],"extraskeletal chondrosarcoma","2026-03-16",{"date":123,"type":32},"2026-03-19",{"date":125,"type":4},"2012-12",{"date":127,"type":19},"2027-12-31",{"name":129,"class":39},"Massachusetts General Hospital",10,{"id":132,"slug":4,"hasResults":10,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":152,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":40},"100626230","NCT07432932","Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients","PANTHR-S","Inclusion Criteria:\n\n* Written informed consent for the prospective cohort\n\n  * Histopathological diagnosis of high-risk soft tissue sarcoma and one of the following subtypes: DDLPS, LMS, SS, vascular sarcomas or MPNST. Other subtypes may be included with PI approval.\n  * High-risk sarcoma definition:\n\n    * Greater than 5cm or Grade 3\n    * Deep anatomic location\n  * Have disease amenable to biopsy\n\n    o Patients who are not amenable to repeat biopsy at baseline can be reviewed with the local site PI for consideration of inclusion to the study\n  * Resectable tumour\n  * Measurable disease by RECIST 1.1\n  * Aged ≥ 18 years\n  * WHO performance status 0-2\n  * For patients receiving NCT, medically fit enough, with adequate organ function, to undergo neoadjuvant chemotherapy\n  * Patients medically fit enough to undergo surgical resection\n  * Capable of giving written informed consent (for prospective cohort) and comply with the study schedule\n  * Patients may also participate in the STRASS 2 trial\n\nExclusion Criteria:\n\n-Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI.\n\n* Known additional malignancy that is progressing or requires active treatment\n* Metastatic disease not amenable to curative intent local therapy\n* Any active uncontrolled medical conditions",{"count":138,"type":19},800,"OBSERVATIONAL","This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), synovial sarcoma (SS), vascular sarcomas, malignant peripheral nerve sheath tumour (MPNST) or other subtypes. It comprises of both retrospective and prospective tissue collection from patients advancing directly to surgery (control group) and patients receiving NCT and surgery.",[142,143,144,145,146,147,148,25,149,26,150,151],"Sarcoma","Sarcoma, Leiomyo-, Adult","Sarcoma, Synovial, Adult","Soft Tissue Sarcoma (STS)","Soft Tissue Sarcoma Adult","Soft Tissue Sarcoma of the Trunk and Extremities","Soft Tissue Sarcoma of the Limb","Liposarcoma, Dedifferentiated","Leiomyosarcoma (LMS)","Angiosarcoma",[153,154,155],"PANTHRS","PANTHRS-S","Sarcoma Accelerator","2026-02-18",{"date":158,"type":32},"2026-02-25",{"date":160,"type":32},"2021-11-19",{"date":162,"type":19},"2028-06-30",{"name":164,"class":39},"Royal Marsden NHS Foundation Trust",{"id":166,"slug":4,"hasResults":10,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":20,"phases":174,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":193,"locationsCount":40},"100623398","NCT07396116","Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)","Preoperative Hypofractionated Radiotherapy Combined With Immunotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-02)","FUSION-02","Inclusion Criteria:\n\n* Diagnosis \\& Indication: Primary or recurrent abdominopelvic soft tissue sarcoma. Patients are deemed to have a high probability of R1\u002FR2 resection with upfront surgery and are confirmed to require radiotherapy following Multidisciplinary Team (MDT) discussion.\n* Target Volume: In cases of multifocal disease, all lesions must be safely encompassable within a single radiotherapy target volume.\n* Age: Age ≥ 18 years.\n* Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status 0-2; American Society of Anesthesiologists (ASA) score ≤ 2; patients must be expected to tolerate surgery and radiotherapy.\n* Pathology: Histologically confirmed soft tissue sarcoma.\n* Measurability: Presence of evaluable lesions.\n* Life Expectancy: Life expectancy \\> 5 years.\n* Hematological \\& Hepatic Function: Adequate organ function\n* Renal Function: Adequate renal function defined as Glomerular Filtration Rate (GFR) ≥ 50 ml\u002Fmin (calculated by Cockcroft-Gault formula), and split renal function imaging confirms function in the contralateral kidney.\n* Contraception: Female patients of childbearing potential, or male patients with female partners of childbearing potential, must agree to use effective contraception during the entire treatment period and for 6 months after the last dose.\n* Consent: Signed informed consent form.\n* Follow-up: Capable of complying with follow-up requirements.\n\nExclusion Criteria:\n\n* Significant Comorbidities: Patients with the following concurrent conditions: active hemorrhage, ulceration, intestinal perforation, intestinal obstruction, uncontrolled hypertension, cardiac insufficiency (NYHA Class III-IV), severe hepatic or renal dysfunction (Grade 4), mesenteric ischemia, or severe inflammatory bowel disease (IBD).\n* Excluded Histologies: Other pathological types, including Gastrointestinal Stromal Tumor (GIST), sarcomatoid carcinoma, sarcomas primarily treated with chemotherapy (e.g., rhabdomyosarcoma and PNET), desmoid fibromatosis, and benign tumors.\n* Unresectability: Tumor invasion into critical structures such as the liver, pancreatic head, or abdominal aorta, rendering the tumor deemed unresectable.\n* Prior Radiotherapy: History of prior radiotherapy to the same anatomical region.\n* Distant Metastasis: Presence of distant metastasis (M1) confirmed by comprehensive imaging\u002Fexamination within 4 weeks prior to enrollment.\n* Contraindications to Surgery\u002FProtocol: Presence of other severe medical comorbidities that contraindicate surgery or preclude participation in the study.\n* Planned Neoadjuvant Chemotherapy: Patients scheduled to receive (concurrent) neoadjuvant chemotherapy.\n* Recent Systemic Therapy: Receipt of chemotherapy or other systemic treatments within 4 weeks prior to enrollment.",{"count":173,"type":19},28,[76],"To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy combined with immunotherapy followed by surgery for retroperitoneal sarcoma",[145,25,177,178,179],"Immunotherapy","Radiotherapy Side Effect","Ultra-hypofractionated Radiotherapy",[181,182,183,184,185],"hypofractionated radiotherapy","retroperitoneal sarcoma","soft tissue sarcoma","immunotherapy","peri-operative complications","NOT_YET_RECRUITING","2026-02-10",{"date":189,"type":32},"2026-02-12",{"date":189,"type":19},{"date":192,"type":19},"2028-12-31",{"name":194,"class":39},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":196,"slug":4,"hasResults":10,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":221},"100588608","NCT06943612","Colorectal Resections in Patients With Retroperitoneal Sarcoma","Colorectal Resections and Reconstructions in Patients With Retroperitoneal Sarcoma: Evaluation of Surgical Strategies and Postoperative Quality of Life","COLOSARC-Q","Inclusion Criteria:\n\n* Histological confirmation with evidence of a retroperitoneal sarcoma\n* Tumor resection with colorectal resection\n* Surgery in a DKG-certified sarcoma center or hospital that meets certification-equivalent criteria\n* Age 18 years or older\n* Written consent\n\nExclusion Criteria:\n\n* Absence of consent",{"count":203,"type":19},120,"COLOSARC-Q is a multicenter study with the objective of providing an up-to-date assessment of colorectal resections and reconstruction techniques in the context of multivisceral resections for retroperitoneal sarcomas, as well as colorectal surgery-associated complications and their impact on patients' quality of life.\n\nIn multivisceral resections involving the colon and rectum, the primary aim is to achieve complete resection and preserve organ function. However, multivisceral resections have a high risk of perioperative morbidity including anastomotic leakage. The proposed project aims to determine the number of primary anastomoses, their insufficiency rates, and the fraction of patients with primary and secondary stomas. In addition, the patients' quality of life after multivisceral sarcoma resection is to be recorded using standardized surveys.\n\nThe analysis has the potential to facilitate intraoperative decision-making for colorectal resections in the context of multivisceral resections.",[206,25],"Sarcoma, Soft Tissue",[208,25,209,210,211],"Soft tissue sarcoma","Sarcoma Surgery","Stoma","Colorectal resection","2025-12-04",{"date":214,"type":32},"2025-12-12",{"date":216,"type":32},"2025-01-27",{"date":218,"type":19},"2026-03",{"name":220,"class":39},"Heidelberg University",13,{"id":223,"slug":4,"hasResults":10,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":20,"phases":231,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":243,"locationsCount":40},"100456541","NCT05224934","Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)","Full-target Ultra-hypofractionated Stereotactic Irradiation Orchestrated With Nodule Boost for Retroperitoneal Sarcoma","FUSION-01","Inclusion Criteria:\n\n* Primary soft tissue sarcoma of retroperitoneal or infra-peritoneal spaces of pelvis\n* Sarcoma not originated from bone structure, abdominal or gynecological viscera\n* All disease can be included safely within one radiotherapy field\n* Absence of extension through the sciatic notch or across the diaphragm\n* Histologically proven, excluding the following subtypes: Gastro-intestinal stromal tumors (GIST), rhabdomyosarcoma, PNET or other small round blue cells sarcoma, osteosarcoma or chondrosarcoma, aggressive fibromatosis, sarcomatoid or metastatic carcinoma\n* ECOG performance status 0 to 2\n* American Society of Anesthesiologist (ASA) score ≤2\n* Normal renal function: Calculated Creatinine Clearance ≥50ml\u002Fmin（by Cockcroft-Gault formula）and functional contralateral kidney by differential renal isotope scan\n* Normal bone marrow and hepatic function.\n* Contraception was needed for female patients of child-bearing age, or male patients whose partner had child-bearing age\n* expected life expectancy longer than 5 years\n* Written consent form was given prior to treatment\n* Can safely be treated by radiotherapy and surgery\n\nExclusion Criteria:\n\n* metastatic disease\n* Tumor was previously treated by radiotherapy\n* Involvement of liver, pancreatic head or duodenum",{"count":230,"type":19},50,[76],"To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy followed by surgery for retroperitoneal sarcoma",[234,25,178,179,235],"Soft Tissue Sarcoma","Stereotactic Ablative Radiotherapy",[237,181,182,183,185],"stereotactic ablative radiotherapy",{"date":239,"type":32},"2025-12-11",{"date":241,"type":32},"2022-01-01",{"date":127,"type":19},{"name":194,"class":39},{"id":245,"slug":4,"hasResults":10,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":20,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":40},"100541255","NCT06327477","Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma","First-in-Human Phase I and II Study to Determine Safety and Efficacy of Proton-Spatially Fractionated Radiotherapy (P-SFRT) in Retroperitoneal Soft Tissue Sarcoma","Inclusion Criteria:\n\n* Patients must have newly diagnosed, histologically or cytologically confirmed, untreated retroperitoneal soft tissue sarcoma\n* The soft-tissue sarcoma tumor must be at least 3 cm in diameter\n* Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.\n* Patients must be age ≥ 18 years on day of signing any informed consent documents\n* Patients must exhibit a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale or \\>70% on the Karnofsky Scale\n* Leukocytes (white blood cells \\[WBC\\]) ≥ 3,000\u002FmcL\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FmcL\n\n  * Note: growth factor\u002Ftransfusion is not permitted prior to these measurements being taken\n* Hemoglobin (Hgb) ≥ 9 g\u002Fd\n* Platelets (PLT) ≥ 100,000\u002FmcL\n* Total bilirubin \\\u003C 1.5 x upper limit of normal (ULN) (or direct bilirubin \\\u003C ULN)\n* Aspartate Transferase (AST) ( serum glutamic-oxaloacetic transaminase \\[SGOT\\]) ≤ 2.5 x institutional ULN\n* Alanine transaminase (ALT) (serum glutamic-pyruvic transaminase \\[SGPT\\]) ≤ 2.5 x institutional ULN\n* Creatinine ≤ 1.5 x upper limit of normal (ULN)\n* Creatinine clearance ≥ 50mL\u002Fmin\n* International normalized ratio (INR) (or prothrombin time \\[PT\\] or partial thromboplastin time \\[PTT\\]; one will be used) \\\u003C 1.5 x ULN (unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants \\[within 10 days of treatment initiation\\])\n* Activated partial thromboplastin time (aPTT) \\\u003C 1.5 X ULN (unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants \\[within 10 days of treatment initiation\\])\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patients of child-bearing potential (POCBP) must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) from time of informed consent and for the duration of study participation. Patients who can impregnate their partners must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) from time of informed consent and for the duration of study participation. Should a patient become pregnant or suspect they are pregnant while they or their partner is participating in this study, they should inform their treating physician immediately.\n\n  * Note: At the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, postovulation methods\\] and withdrawal are not acceptable methods of contraception.)\n  * Note: A POCBP is any person with an egg-producing reproductive tract (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n    * Has not undergone a hysterectomy or bilateral oophorectomy\n    * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n* POCBP must have a negative urine pregnancy test within 72 hours prior to undergoing CT simulation for P-SFRT. If a urine pregnancy test is positive or cannot be confirmed negative, a serum pregnancy test will be required\n* POCBP must be willing and able to use an adequate method of contraception\n* Patients with sperm-producing reproductive capacity (PWSPRC) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from time of informed consent, for the duration of study participation, and for 120 days following completion of therapy. PWSPRC treated or enrolled on this protocol must also agree to refrain from donating sperm from time of informed consent for the duration of study participation and for 120 days following completion of therapy\n* Patients must have the ability to understand and the willingness to sign a written informed consent document\n* Patients must be medically fit to undergo surgery\n* Patients must have plans to undergo neoadjuvant radiation therapy and surgery with curative intent\n\nExclusion Criteria:\n\n* Patients who have had one of the following soft tissue sarcoma subtypes where neoadjuvant chemotherapy is established as standard-of-care:\n\n  * Extra-skeletal Ewing sarcoma\n  * Embryonal rhabdomyosarcoma\n  * Alveolar rhabdomyosarcoma\n  * Desmoplastic small round cell tumor\n* Patients who have had any prior radiation therapy to the affected area\n* Patients who have had chemotherapy, radiotherapy, or other antineoplastic agents ≤ 28 days (6 weeks for nitrosureas or mitomycin C) prior to planned treatment start date\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia\n* Patients who have taken steroid therapy or any other immunosuppressive therapy within 7 days of first dose prior to trial treatment\n* Patients with a known history of active tuberculosis (TB) (Bacillus tuberculosis)\n* Patients with a known history of active hepatitis B (e.g., hepatitis B surface antigen \\[HBsAg\\] reactive) or hepatitis C (e.g., hepatitis C virus \\[HCV\\] ribonucleic acid \\[RNA\\] \\[qualitative\\] is detected) infection\n* Patients with current or a history of any distant metastatic disease (including brain). Note: an isolated or oligo-metastatic regional occurrence may be allowed if all other criteria have been met and curative attempt is being pursued\n* Patients with a known history of (non-infectious) pneumonitis that required steroids or had evidence of current pneumonitis\n* Patients who have received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally killed virus vaccines, and as such, patients who have received these vaccines are not excluded; however, intranasal influenza vaccines are live attenuated vaccines and are not allowed\n* Patients who have had an allogenic tissue\u002Fsolid organ transplant\n* Patients with a history of inflammatory bowel disorders (i.e., ulcerative colitis, Crohn's disease) or rheumatologic disorders (i.e., Sjogren's, scleroderma, rheumatoid arthritis) that serve as a contraindication to retroperitoneal radiation therapy\n* Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible:\n\n  * Hypertension that is not controlled on medication\n  * Ongoing or active infection requiring systemic treatment\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Major surgery within 30 days of registration\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient¡¦s safety or study endpoints\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Patients who are pregnant (positive urine pregnancy test within 72 hours prior to enrollment) or nursing. If a urine pregnancy test is positive or cannot be confirmed negative, a serum pregnancy test will be required\n* Patients who are expecting to become pregnant or impregnate their partner within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\n* Patients who are currently participating in or have participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention\n* Other study specific or disease criteria for exclusion (e.g., certain disease sub-types that are not eligible, patients who are unable to swallow oral medication if the study involves oral agents, etc.)",{"count":173,"type":19},[22,116],"This phase I\u002FII trial studies the side effects and best dose of proton-spatially fractionated radiotherapy (P-SFRT) and to see how well it works with standard radiation therapy in treating patients with newly diagnosed retroperitoneal soft tissue sarcoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard spatially fractionated radiotherapy (SFRT) refers to how the radiation is delivered to the tumor. SFRT means that different parts of the tumor are receiving different doses of radiation (fractionation) through beams that allow areas of higher and lower (peaks and valleys) of doses of the radiation. This spatial fractionation allows an overall high-dose radiation to be given in the peaks and those areas of the tumor may release cells and substances that may help with killing tumor cells, reducing tumor symptoms and shrinking tumors. Proton therapy is a type of radiation therapy that can overcome some of the barriers of standard SFRT. Protons are tiny radioactive particles that can be controlled in a beam to travel up to the tumor and, compared to the particles used in standard radiotherapy, proton therapy can deliver higher doses to the tumor because smaller doses of radiation are delivered to tissues away from the tumor. This allows radiation therapy dose-escalated (continuously increasing the dose of radiation) treatment to tumors even though the tumor is near radiation sensitive organs like the colon. Giving P-SFRT with standard radiation therapy may work better in treating patients with newly diagnosed retroperitoneal soft tissue sarcoma.",[25],"2025-10-15",{"date":256,"type":32},"2025-10-20",{"date":258,"type":32},"2024-04-02",{"date":260,"type":19},"2028-07-01",{"name":262,"class":39},"Northwestern University",{"id":264,"slug":4,"hasResults":10,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":20,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":40},"100578496","NCT06812052","Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery","Prospective Phase I Trial of Hypofractionated Radiation Therapy in Retroperitoneal Sarcoma","Inclusion Criteria:\n\n* Participants must have a histologically confirmed STS of the retroperitoneal space or infra-peritoneal spaces of pelvis\n* Participant must have radiologically measurable disease (RECIST 1.1), as confirmed by abdomino-pelvic CT or MRI\n* Participant must have primary, locally recurrent, or metastatic disease requiring treatment of the retroperitoneal mass\n* Tumor must be suitable for radiotherapy and surgery based on pre-treatment CT scan\u002FMRI in multidisciplinary discussion with surgeon and radiation oncologist (anticipated macroscopically complete resection, R0\u002FR1 resection)\n* Age: 18 years or older\n* ECOG performance status ≤2\n* Absence of history of bowel obstruction, mesenteric ischemia, or severe chronic inflammatory bowel disease.\n* Normal renal function (calculated creatinine clearance ≥50 mL\u002Fmin)\n* Normal bone marrow and hepatic function (white blood cell count ≥2·5 × 10⁹ cells per L, platelet count ≥80 × 10⁹ cells per L, and total bilirubin \\\u003C2 times upper limit of normal)\n* Women of child-bearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment\n* Patients capable of childbearing\u002Freproductive potential should use adequate contraception\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Sarcoma originating from bone structure, abdominal or gynecological viscera\n* Any of the following histological subtypes: gastrointestinal stromal tumor, rhabdomyosarcoma, primitive neuroectodermal tumor or other small round blue cell sarcoma, osteosarcoma, chondrosarcoma, aggressive fibromatosis, or sarcomatoid or metastatic carcinoma\n* Prior RT to the RPS\n* Prior abdominal or pelvic irradiation for other prior malignancy or other disease\n* Prior different invasive malignancy may be eligible per the discretion of the treating investigator and review by the Principal Investigator (PI)\n* Prior chemotherapy or immunotherapy within 6 weeks of start of RT\n* Pregnant women are excluded from this study because RT has the potential for teratogenic or abortifacient effects.\n* HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for increased sensitivity to RT",{"count":270,"type":19},6,[22],"To determine the safety of moderately hypofractionated radiation in the treatment of primary and locally recurrent RPS, based on the evaluation of acute radiation-related toxicity profile of each participant (30-day radiation toxicity)",[25],"2025-10-11",{"date":276,"type":32},"2025-10-14",{"date":278,"type":32},"2025-05-29",{"date":280,"type":19},"2026-11",{"name":282,"class":39},"Brigham and Women's Hospital",{"id":284,"slug":4,"hasResults":10,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":290,"targetDuration":292,"studyType":139,"phases":4,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":310},"100350123","NCT03838718","REtroperitoneal SArcoma Registry: an International Prospective Initiative","REtroperitoneal SArcoma Registry (RESAR): Prospective Collection of Primary Retroperitoneal Sarcoma Patient's Data, Radiological and Pathological Material for the TransAtlantic Retroperitoneal Sarcoma Working Group","RESAR","Inclusion Criteria:\n\n* primary RPS operated on in the participating center;\n* age\\>18 years at the time of the first treatment (pediatric patients can not be included)\n* histological confirmed diagnosis according to the WHO criteria done on biopsy or surgical specimen by dedicated sarcoma pathologist;\n* radiological examinations performed (contrast enhanced abdominal CT scan and\u002For MRI) prior to surgical resection;\n* signed informed consent form;\n* adequate compliance of the patients to the plan of follow-up\n\nExclusion Criteria:\n\n* age\\\u003C18 years;\n* recurrent tumor;\n* benign retroperitoneal tumors;\n* serious psychiatric disease that precludes informed consent or limits compliance;\n* impossibility to ensure adequate follow-up",{"count":291,"type":19},2000,"10 Years","Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority.\n\nPrimary Objectives of this study are:\n\n* to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers.\n* patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM).\n\nSecondary Objectives:\n\n* to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS;\n* to prospectively evaluate the impact of multimodality therapy, including radiation therapy and chemotherapy;\n* to identify clinical, radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR\u002FDM\u002FOS. These may be important biomarkers of disease;\n* to utilize collected pathological material for research collaborations.",[25],[142,296,297,298,299,300],"Surgery","Multivisceral resection","Chemotherapy","Radiation Therapy","Patients' Registry","2019-02-11",{"date":303,"type":32},"2019-02-12",{"date":305,"type":32},"2016-09-01",{"date":307,"type":19},"2030-12-31",{"name":309,"class":39},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",22,""]